Combinatorial therapy using dovitinib and ICI182.780 (Fulvestrant) blocks tumoral activity of endometrial cancer cells

Molecular Cancer Therapeutics

Volumn 13, Issue 4, 2014, Pages 776-787

  Eritja, Nuria ^a,b   Domingo, Mónica ^a,b   Dosil, Maria Alba ^a,b   Mirantes, Cristina ^a,b   Santacana, Maria ^a,b   Valls, Joan ^a,b   Llombart Cussac, Antonio ^a   Matias Guiu, Xavier ^a,b   Dolcet, Xavier ^a,b  

^a HOSPITAL ARNAU DE VILANOVA   (Spain)

^b HOSPITAL UNIVERSITARI ARNAU DE VILANOVA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; CASPASE 9; CYCLIN D1; DOVITINIB; ESTROGEN RECEPTOR ALPHA; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FULVESTRANT; MITOGEN ACTIVATED PROTEIN KINASE; P21 ACTIVATED KINASE; PROTEIN KINASE B; PROTEIN P14; PROTEIN P16; STAT3 PROTEIN; TUBULIN; 4-AMINO-5-FLUORO-3-(5-(4-METHYLPIPERAZIN-1-YL)-1H-BENZIMIDAZOL-2-YL)QUINOLIN-2(1H)-ONE; ANTINEOPLASTIC AGENT; BENZIMIDAZOLE DERIVATIVE; ESTRADIOL; QUINOLONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER REGRESSION; CANCER SIZE; CARCINOMA CELL; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; ENDOMETRIUM CARCINOMA; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CYCLE; DRUG EFFECTS; DRUG SCREENING; ENDOMETRIAL NEOPLASMS; EXPERIMENTAL NEOPLASM; GENETICS; METABOLISM; MUTATION; PATHOLOGY; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZIMIDAZOLES; CELL CYCLE; CELL LINE, TUMOR; ENDOMETRIAL NEOPLASMS; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; MICE; MICE, SCID; MUTATION; NEOPLASMS, EXPERIMENTAL; QUINOLONES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84912074348     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0794     Document Type: Article

References (50)

1. Pectasides D, Pectasides E, Economopoulos T. Systemic therapy in metastatic or recurrent endometrial cancer. Cancer Treat Rev 2007;33:177-90.
2. Matias-Guiu X, Catasus L, Bussaglia E, Lagarda H, Garcia A, Pons C, et al. Molecular pathology of endometrial hyperplasia and carcinoma. Hum Pathol 2001;32:569-77.
3. Ambros RA, Sherman ME, Zahn CM, Bitterman P, Kurman RJ. Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation. Hum Pathol 1995;26:1260-7.
4. Bussaglia E, del Rio E, Matias-Guiu X, Prat J. PTEN mutations in endometrial carcinomas: a molecular and clinicopathologic analysis of 38 cases. Hum Pathol 2000;31:312-7.
5. Lagarda H, Catasus L, Arguelles R, Matias-Guiu X, Prat J. K-ras mutations in endometrial carcinomas with microsatellite instability. J Pathol 2001;193:193-9.
6. Moreno-Bueno G, Hardisson D, Sanchez C, Sarrio D, Cassia R, Garcia-Rostan G, et al. Abnormalities of the APC/beta-catenin pathway in endometrial cancer. Oncogene 2002;21:7981-90.
7. Catasus L, Machin P, Matias-Guiu X, Prat J. Microsatellite instability in endometrial carcinomas: clinicopathologic correlations in a series of 42 cases. Hum Pathol 1998;29:1160-4.
8. Pollock PM, Gartside MG, Dejeza LC, Powell MA, Mallon MA, Davies H, et al. Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene 2007;26:7158-62.
9. Byron SA, Gartside MG, Wellens CL, Mallon MA, Keenan JB, Powell MA, et al. Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation. Cancer Res 2008;68:6902-7.
10. Dutt A, Salvesen HB, Chen TH, Ramos AH, Onofrio RC, Hatton C, et al. Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci U S A 2008;105:8713-7.
11. Gatius S, Velasco A, Azueta A, Santacana M, Pallares J, Valls J, et al. FGFR2 alterations in endometrial carcinoma. Mod Pathol 2011;24:1500-10.
12. Byron SA, Gartside M, Powell MA, Wellens CL, Gao F, Mutch DG, et al. FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features. PLoS ONE 2012;7:e30801.
13. Kim KB, Chesney J, Robinson D, Gardner H, Shi MM, Kirkwood JM. Phase I/II and pharmacodynamic study of dovitinib (TKI258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, in patients with advanced melanoma. Clin Cancer Res 2011;17:7451-61.
14. Suzuki H, Suda N, Shiga M, Kobayashi Y, Nakamura M, Iseki S, et al. Apert syndrome mutant FGFR2 and its soluble form reciprocally alter osteogenesis of primary calvarial osteoblasts. J Cell Physiol 2012;227:3267-77.
15. Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 2010;10:116-29.
16. Lee SH, Lopes de Menezes D, Vora J, Harris A, Ye H, Nordahl L, et al. In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models. Clin Cancer Res 2005;11:3633-41.
17. Renhowe PA, Pecchi S, Shafer CM, Machajewski TD, Jazan EM, Taylor C, et al. Design, structure-activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: a novel class of receptor tyrosine kinase inhibitors. J Med Chem 2009;52:278-92.
18. Dey JH, Bianchi F, Voshol J, Bonenfant D, Oakeley EJ, Hynes NE. Targeting fibroblast growth factor receptors blocks PI3K/AKT signaling, induces apoptosis, and impairs mammary tumor outgrowth and metastasis. Cancer Res 2010;70:4151-62.
19. Konecny GE, Kolarova T, O'Brien NA, Winterhoff B, Yang G, Qi J, et al. Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells. Mol Cancer Ther 2013;12:632-42.
20. Huynh H. Molecularly targeted therapy in hepatocellular carcinoma. Biochem Pharmacol 2010;80:550-60.
21. Pertschuk LP, Masood S, Simone J, Feldman JG, Fruchter RG, Axiotis CA, et al. Estrogen receptor immunocytochemistry in endometrial carcinoma: a prognostic marker for survival. Gynecol Oncol 1996;63:28-33.
22. Emons G, Günthert A, Thiel FC, Camara O, Strauss HG, Breitbach GP, et al. Phase II study of fulvestrant 250 mg/month in patients with recurrent or metastatic endometrial cancer: a study of the Arbeitsgemeinschaft Gynäkologische Onkologie. Gynecol Oncol 2013;129:495-9.
23. Llobet D, Eritja N, Domingo M, Bergada L, Mirantes C, Santacana M, et al. KSR1 is overexpressed in endometrial carcinoma and regulates proliferation and TRAIL-induced apoptosis by modulating FLIP levels. Am J Pathol 2011;178:1529-43.
24. Eritja N, Llobet D, Domingo M, Santacana M, Yeramian A, Matias-Guiu X, et al. Anovel three-dimensional culture systemof polarized epithelial cells to study endometrial carcinogenesis. Am J Pathol 2010;176:2722-31.
25. Eritja N, Mirantes C, Llobet D, Masip G, Matias-Guiu X, Dolcet X. ERα-mediated repression of pro-inflammatory cytokine expression by glucocorticoids reveals a crucial role for TNFα and IL1α in lumen formation and maintenance. J Cell Sci 2012;125:1929-44.
26. Macia A, Gallel P, Vaquero M, Gou-Fabregas M, Santacana M, Maliszewska A, et al. Sprouty1 is a candidate tumor-suppressor gene in medullary thyroid carcinoma. Oncogene 2012;31:3961-72
27. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
28. Yeramian A, Sorolla A, Velasco A, Santacana M, Dolcet X, Valls J, et al. Inhibition of activated receptor tyrosine kinases by Sunitinib induces growth arrest and sensitizes melanoma cells to Bortezomib by blocking Akt pathway. Int J Cancer 2012;130:967-78.
29. Braig M, Schmitt CA. Oncogene-induced senescence: putting the brakes on tumor development. Cancer Res 2006;66:2881-4.
30. Campisi J, d'Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 2007;8:729-40.
31. Cerliani JP, Vanzulli SI, Piñero CP, Bottino MC, Sahores A, Nuñez M, et al. Associated expressions of FGFR-2 and FGFR-3: from mouse mammary gland physiology to human breast cancer. Breast Cancer Res Treat 2012;133:997-1008.
32. Dauvois S, White R, Parker MG. The antiestrogen ICI182.780 disrupts estrogen receptor nucleocytoplasmic shuttling. J Cell Sci 1993;106 (Pt 4):1377-88.
33. Gibson MK, Nemmers LA, Beckman WC, Davis VL, Curtis SW, Korach KS. The mechanism of ICI 164,384 antiestrogenicity involves rapid loss of estrogen receptor in uterine tissue. Endocrinology 1991;129:2000-10.
34. Eritja N, Mirantes C, Llobet D, Yeramian A, Bergadá L, Dosil MA, et al. Long-term estradiol exposure is a direct mitogen for insulin/EGFprimed endometrial cells and drives PTEN loss-induced hyperplasic growth. Am J Pathol 2013;183:277-87.
35. Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 1995;270:1491-4.
36. Bansal N, Yendluri V, Wenham RM. The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer Control 2009;16:8-13.
37. Byron SA, Pollock PM. FGFR2 as a molecular target in endometrial cancer. Future Oncol 2009;5:27-32.
38. Temkin SM, Fleming G. Current treatment of metastatic endometrial cancer. Cancer Control 2009;16:38-45.
39. Covens AL, Filiaci V, Gersell D, Lutman CV, Bonebrake A, Lee YC. Phase II study of fulvestrant in recurrent/metastatic endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2011;120:185-8.
40. Issa A, Gill JW, Heideman MR, Sahin O, Wiemann S, Dey JH, et al. Combinatorial targeting of FGF and Erbb receptors blocks growth and metastatic spread of breast cancer models. Breast Cancer Res 2013;15:R8.
41. Angevin E, Lopez-Martin JA, Lin CC, Gschwend JE, Harzstark A, Castellano D, et al. Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma. Clin Cancer Res 2013;19:1257-68.
42. Chen KF, Chen HL, Liu CY, Tai WT, Ichikawa K, Chen PJ, et al. Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3. Biochem Pharmacol 2012;83:769-77.
43. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
44. Ishii K, Imamura T, Iguchi K, Arase S, Yoshio Y, Arima K, et al. Evidence that androgen-independent stromal growth factor signals promote androgen-insensitive prostate cancer cell growth in vivo. Endocr Relat Cancer 2009;16:415-28.
45. Imagawa W, Pedchenko VK, Helber J, Xing C. Attenuation and loss of hormonal modulation of KGF (FGF-7)/KGF receptor expression and mitogenesis during mammary tumor progression. J Cell Physiol 2000;184:222-8.
46. de Vincenzo R, Scambia G, Benedetti Panici P, Bonanno G, Ercoli A, Fattorossi A, et al. Chemosensitizing effect of tamoxifen and ICI182.780 on parental and adriamycin-resistant MCF-7 human breast cancer cells. Ann N Y Acad Sci 1996;784:517-20.
47. Sui M, Huang Y, Park BH, Davidson NE, Fan W. Estrogen receptor α mediates breast cancer cell resistance to paclitaxel through inhibition of apoptotic cell death. Cancer Res 2007;67:5337-44.
48. Sui M, Jiang D, Hinsch C, Fan W. Fulvestrant (ICI182.780) sensitizes breast cancer cells expressing estrogen receptor alpha to vinblastine and vinorelbine. Breast Cancer Res Treat 2010;121:335-45.
49. Ikeda H, Taira N, Nogami T, Shien K, Okada M, Shien T, et al. Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel, docetaxel, vinorelbine, and 5-fluorouracil) has a synergistic effect in estrogen receptor-positive breast cancer. Cancer Sci 2011;102:2038-42.
50. Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 2012;487:505-9. University